Biopharma's winners and losers of 2025
2025年生物醫藥業的贏家與輸家
What a year! The XBI is up, M&A is bumping and the vibes are improving. But it ain’t all Christmas cookies. As has become our tradition, we kept track of who was up and who was down in 2025 to take stock of the year in ideas, people, drugs and companies.
多事之秋！XBI走高，兼并收購回暖，市場情緒也在轉好。但并非盡是圣誕甜餅。照例，我們統計了2025年里在創意、人物、藥物與公司層面誰在上行、誰在下行，以盤點這一年的風向。
本報道最初發表于Endpoints News。請點擊這里查看原文
What a year! The XBI is up, M&A is bumping and the vibes are improving. But it ain’t all Christmas cookies. As has become our tradition, we kept track of who was up and who was down in 2025 to take stock of the year in ideas, people, drugs and companies.
真是精彩的一年！XBI上漲，M&A活躍，整體氛圍在好轉。不過也不全是“圣誕曲奇”。按照我們的慣例，我們梳理了2025年里誰在上行、誰在下行，總結這一年的創意、人物、藥物與公司。
您已閱讀4%（374字），剩余96%（8550字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。